Skip to content
OpenCapital
Get started

BioCryst Pharmaceuticals BCRX Operating Lease Weighted Average Discount Rate Percent

Operating Lease Weighted Average Discount Rate Percent at other companies

Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
——
Precigen logo
PrecigenPGEN
——

Other financials

Income statement

See full
Revenue$156.4M+7.5%
Gross profit$151.0M+7.1%
Operating income-$701.6M-3,405%
Net income-$721.8M-2,255,763%
EPS (diluted)-$2.98—

Balance sheet

See full
Cash & equivalents$173.4M+62.2%
Total debt$411.8M+24.7%
Total equity-$553.8M-22.6%
Total assets$465.1M-3.1%

Cash flow

See full
Operating cash flow-$61.8M-125%
CapEx$403.0K+182%
Free cash flow-$62.2M-125%

Valuation

See full
Market cap$2.37B+52.3%
Enterprise value$2.6B+46.7%
P/S2.7×-0.4×

Profitability

See full
Gross margin97.8%+0.8pp
Operating margin-43.1%-49.7pp
Net margin-51.7%-69.7pp
FCF margin35%—

Returns & leverage

See full
Return on equity-882.8%—
Debt / equity0.1×—
Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's operating lease weighted average discount rate percent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioCryst Pharmaceuticals's operating lease weighted average discount rate percent?
BioCryst Pharmaceuticals (BCRX) reported operating lease weighted average discount rate percent of $0.1 in Q1 2026.
How has BioCryst Pharmaceuticals's operating lease weighted average discount rate percent changed year-over-year?
BioCryst Pharmaceuticals's operating lease weighted average discount rate percent decreased by 7.9% year-over-year, from $0.11 to $0.1.
What is the long-term trend for BioCryst Pharmaceuticals's operating lease weighted average discount rate percent?
Over 3 years (2022 to 2025), BioCryst Pharmaceuticals's operating lease weighted average discount rate percent has grown at a -0.9% compound annual growth rate (CAGR), from $0.11 to $0.11.